Citizens JMP analyst Jonathan Wolleben raised the firm’s price target on BioCryst (BCRX) to $27 from $17 and keeps an Outperform rating on the shares. BioCryst is buying Astria Therapeutics (ATXS) to “supercharge” its earnings growth with long- acting HAE candidate navenibart, the analyst tells investors in a research note. The firm expects 3 month and 6 month navenibart doses to hit in Astria’s ongoing Phase 3 trial in early 2027 and believe its differentiated, long-acting convenience, coupled with impressive efficacy, will drive broad adoption right as BioCryst’s Orladeyo hits its peak penetration.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst reinstated with a Buy at TD Cowen
- BioCryst weakness presents ‘compelling’ buying opportunity, says RBC
- BioCryst’s Strategic Acquisition of ATXS: A Catalyst for Long-Term Growth and Profitability
- BioCryst’s Strategic Acquisition of Astria Therapeutics Boosts Market Position and Financial Outlook
- BioCryst price target raised to $15 from $14 at Jefferies